VERVライブシグナル | Getagraph.comで利益を最大化

売る 107847 min ago

@ $12.71

発行日: 15 2月 2024 @ 04:22

リターン: -48.86%

前回のシグナル: 2月 15 - 02:04

前回のシグナル: 買う

リターン: 0.87 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:48):

Stats
本日の出来高	298 870
平均出来高	1.30M
時価総額	510.57M
EPS	$0 ( 2024-03-07 )
次の収益日	( $-0.680 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.08
ATR14	$0.0110 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Nickerson Joan	Buy	3 315	Common Stock
2024-04-01	Nickerson Joan	Sell	3 315	Restricted Stock Units
2024-04-02	Nickerson Joan	Sell	1 514	Common Stock
2024-02-14	Ashe Andrew D.	Buy	150 000	Stock Option (right to buy)
2024-02-14	Ashe Andrew D.	Buy	36 000	Restricted Stock Units

INSIDER POWER
78.58
Last 97 transactions
Buy: 4 843 517 \| Sell: 1 394 833

ボリューム相関

長: -0.04 (neutral)

短: 0.21 (neutral)

Signal:(63.135) Neutral

Verve Therapeutics, Inc. 相関

10 最も正の相関
SVOK	0.939
BIOL	0.915
ARVN	0.9
TSP	0.886
TIL	0.885
UK	0.884
YMAB	0.88
AVCT	0.879
FCACU	0.874
TFFP	0.873

10 最も負の相関
BOCH	-0.93
SHSP	-0.897
LMRK	-0.881
QADA	-0.877
VLYPO	-0.863
RAVN	-0.852
NETE	-0.84
MMSI	-0.837
NRIM	-0.836
MDLZ	-0.83

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Verve Therapeutics, Inc. 相関 - 通貨/商品

-0.56
( weak negative )

-0.78
( moderate negative )

0.00
( neutral )

0.80
( moderate )

0.67
( moderate )

Verve Therapeutics, Inc. 財務諸表

Annual	2023
収益:	$11.76M
総利益:	$6.30M (53.61 %)
EPS:	$-3.12

FY	2023
収益:	$11.76M
総利益:	$6.30M (53.61 %)
EPS:	$-3.12

FY	2022
収益:	$1.94M
総利益:	$-4.77M (-245.75 %)
EPS:	$-2.91

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-6.78

Financial Reports:

No articles found.

Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.